←Back to Expert Scholars
Translational Medicine / 转化医学GVHD, Belumosudil and Ruxolitinib
Madan Jagasia
MBBS, MS
🏢Sarah Cannon Research Institute🌐USA
Chief Medical Officer
80
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Madan Jagasia led pivotal trials of belumosudil and ruxolitinib for steroid-refractory chronic and acute GVHD. He previously directed HCT at Vanderbilt and now leads clinical research at Sarah Cannon. His work shaped modern GVHD drug approvals.
Share:
🧪Research Fields 研究领域
chronic GVHD
belumosudil
ruxolitinib
allogeneic HCT
clinical trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Madan Jagasia 的研究动态
Follow Madan Jagasia's research updates
留下邮箱，当我们发布与 Madan Jagasia（Sarah Cannon Research Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment